Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), announced that Nanoviricides CEO Dr Anil Diwan joined ...

A new way to stop viruses: Boosting your body’s natural defenses

In the ongoing fight against viruses, a new scientific approach could bring sweeping change. Instead of targeting the virus ...

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...
TipRanks on MSN

Assembly Biosciences’ Promising HSV-2 Treatment Study: Key Insights for Investors

Assembly Biosciences Inc (($ASMB)) announced an update on their ongoing clinical study. Study Overview: Assembly Biosciences Inc. is conducting a ...

First high-resolution structure of key herpes virus protein opens path to new antivirals

An international research team has determined the first high-resolution structures of the herpes simplex virus origin-binding ...
Medscape

Study: Rate of Dermatologic Disease in HIV Plunges, but Some Groups Remain Vulnerable

A study of an urban US population reports a sharp decline in dermatologic disease in people with newly diagnosed HIV and ...

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides – NV-387 Broad-Spectrum Antiviral with Activity Against ...

SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong ...
Business Insider

Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnet Pritelivir Phase 2 results supported FDA Breakthrough Therapy ...

The Herpes Hope: How a Modified Virus Is Giving New Options to Patients With Untreatable Skin Cancer

A genetically engineered herpes virus may offer a new and effective treatment for advanced melanoma, providing hope for ...

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains its dual-track, rapid clinical development strategy for ...

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene ...